Uso da dexametasona em pueperas com sindrome HELLP : ensaio clinico randomizado controlado com placebo / Postpartum dexamethasone for women with HELLP syndrome : a double-blind, placebo-contrled, randomized clinical trial

AUTOR(ES)
DATA DE PUBLICAÇÃO

2007

RESUMO

Objective: The purpose of this study was to determine the effectivity of postpartum dexamethasone in patients with HELLP syndrome. Study Design: A prospective, randomized, double-blind trial was conducted including 105 women with HELLP syndrome who were assigned randomly to treatment (n=56) or placebo (n=49) groups, after delivery. The treatment (dexamethasone 10mg or placebo) was administered every 12 hours for four days and an intention to treat analysis was carried out. The analysis variables were duration of hospitalization, maternal morbidity, and the behavior of laboratorial and clinical parameters. Data were analyzed by X2 or Fisher´s exact tests, considering significant a value of p<0.05. Behavior of laboratorial and clinical variables during and after treatment was evaluated by linear model adjustments. Results: Before treatment, no significant difference was observed between the two groups. Mean duration of hospitalization (10 days) was the same in both groups. Maternal morbidity did not differ between groups, considering each complication or when analyzed globally. Rescue scheme was used in 12.5% of the dexamethasone and 18.8% in the placebo group. The use of blood products was not statistically different between groups. Linear model adjustments were used and there was no significant difference between groups considering the pattern of recovery of platelet count (p = 0.84), AST (p = 0.59), LDH (p = 0.647), hemoglobin (p=0.43) and diuresis (p = 0.31). Conclusions: The results of this RCT do not support the use of dexamethasone in the puerperium for recovery of patients with HELLP syndrome

ASSUNTO(S)

hellp syndrome sindrome hellp dexametosona dexamethasone puerperio postpartum period

ACESSO AO ARTIGO

Documentos Relacionados